Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Parkinson's Disease

  Free Subscription


Articles published in Exp Neurol

Retrieve available abstracts of 31 articles:
HTML format



Single Articles


    December 2022
  1. THOMSEN M, Stoica A, Christensen KV, Fryland T, et al
    Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Exp Neurol. 2022;358:114209.
    PubMed     Abstract available


    October 2022
  2. LAI HJ, Deng CR, Wang RW, Lee LN, et al
    The genesis and functional consequences of cortico-subthalamic beta augmentation and excessive subthalamic burst discharges after dopaminergic deprivation.
    Exp Neurol. 2022;356:114153.
    PubMed     Abstract available


    August 2022
  3. DE LUZY IR, Pavan C, Moriarty N, Hunt CPJ, et al
    Identifying the optimal developmental age of human pluripotent stem cell-derived midbrain dopaminergic progenitors for transplantation in a rodent model of Parkinson's disease.
    Exp Neurol. 2022 Aug 30:114219. doi: 10.1016/j.expneurol.2022.114219.
    PubMed     Abstract available


  4. MEIER JM, Perdikis D, Blickensdorfer A, Stefanovski L, et al
    Virtual deep brain stimulation: Multiscale co-simulation of a spiking basal ganglia model and a whole-brain mean-field model with The Virtual Brain.
    Exp Neurol. 2022;354:114111.
    PubMed     Abstract available


    June 2022
  5. BELOVA ECAPITAL EM, CYRILLIC, Filyushkina VI, Dzhalagoniia I, Gamaleya AA, et al
    Oscillations of pause-burst neurons in the STN correlate with the severity of motor signs in Parkinson's disease.
    Exp Neurol. 2022 Jun 27:114155. doi: 10.1016/j.expneurol.2022.114155.
    PubMed     Abstract available


  6. DARCY N, Lofredi R, Al-Fatly B, Neumann WJ, et al
    Spectral and spatial distribution of subthalamic beta peak activity in Parkinson's disease patients.
    Exp Neurol. 2022 Jun 19:114150. doi: 10.1016/j.expneurol.2022.114150.
    PubMed     Abstract available


  7. HUSSEIN A, Tielemans A, Baxter MG, Benson DL, et al
    Cognitive deficits and altered cholinergic innervation in young adult male mice carrying a Parkinson's disease Lrrk2(G2019S) knockin mutation.
    Exp Neurol. 2022 Jun 19:114145. doi: 10.1016/j.expneurol.2022.114145.
    PubMed     Abstract available


  8. RAUSCHENBERGER L, Guttler C, Volkmann J, Kuhn A, et al
    A translational perspective on pathophysiological changes of oscillatory activity in dystonia and parkinsonism.
    Exp Neurol. 2022 Jun 8:114140. doi: 10.1016/j.expneurol.2022.114140.
    PubMed     Abstract available


    May 2022
  9. WIEST C, Torrecillos F, Tinkhauser G, Pogosyan A, et al
    Finely-tuned gamma oscillations: Spectral characteristics and links to dyskinesia.
    Exp Neurol. 2022;351:113999.
    PubMed     Abstract available


    April 2022
  10. PARR-BROWNLIE LC, Itoga CA, Walters JR, Underwood CF, et al
    Oscillatory waveform sharpness asymmetry changes in motor thalamus and motor cortex in a rat model of Parkinson's disease.
    Exp Neurol. 2022 Apr 21:114089. doi: 10.1016/j.expneurol.2022.114089.
    PubMed     Abstract available


    March 2022
  11. PEREIRA MCL, Boese AC, Murad R, Yin J, et al
    Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage.
    Exp Neurol. 2022 Mar 7:114042. doi: 10.1016/j.expneurol.2022.114042.
    PubMed     Abstract available


    February 2022
  12. WENGER N, Vogt A, Skrobot M, Garulli EL, et al
    Rodent models for gait network disorders in Parkinson's disease - a translational perspective.
    Exp Neurol. 2022 Feb 14:114011. doi: 10.1016/j.expneurol.2022.114011.
    PubMed     Abstract available


  13. PENG Y, Schoneberg N, Esposito MS, Geiger JRP, et al
    Current approaches to characterize micro- and macroscale circuit mechanisms of Parkinson's disease in rodent models.
    Exp Neurol. 2022;351:114008.
    PubMed     Abstract available


    January 2022
  14. MIZRAHI-KLIGER AD, Feldmann LK, Kuhn AA, Bergman H, et al
    Etiologies of insomnia in Parkinson's disease - Lessons from human studies and animal models.
    Exp Neurol. 2022;350:113976.
    PubMed     Abstract available


  15. BUSCH JL, Feldmann LK, Kuhn AA, Rosenblum M, et al
    Real-time phase and amplitude estimation of neurophysiological signals exploiting a non-resonant oscillator.
    Exp Neurol. 2022;347:113869.
    PubMed     Abstract available


    November 2021
  16. OH T, Daadi ES, Kim J, Daadi EW, et al
    Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease.
    Exp Neurol. 2021;347:113920.
    PubMed     Abstract available


    October 2021
  17. MA J, Sun W, Chen S, Wang Z, et al
    The long noncoding RNA GAS5 potentiates neuronal injury in Parkinson's disease by binding to microRNA-150 to regulate Fosl1 expression.
    Exp Neurol. 2021;347:113904.
    PubMed     Abstract available


    September 2021
  18. CHATURVEDI RK, Shukla S, Seth K, Agrawal AK, et al
    Corrigendum to "Zuckerkandl's organ improves long-term survival and function of neural stem cell's derived dopaminergic neurons in parkinsonian rats" [Experimental Neurology Volume 210, Issue 2, April 2008, Pages 608-623].
    Exp Neurol. 2021 Sep 11:113859. doi: 10.1016/j.expneurol.2021.113859.
    PubMed    


  19. YEH TH, Liu HF, Chiu CC, Cheng ML, et al
    PLA2G6 mutations cause motor dysfunction phenotypes of young-onset dystonia-parkinsonism type 14 and can be relieved by DHA treatment in animal models.
    Exp Neurol. 2021 Sep 11:113863. doi: 10.1016/j.expneurol.2021.113863.
    PubMed     Abstract available


    July 2021
  20. LEE JE, Kim HN, Kim DY, Shin YJ, et al
    Memantine exerts neuroprotective effects by modulating alpha-synuclein transmission in a parkinsonian model.
    Exp Neurol. 2021 Jul 13:113810. doi: 10.1016/j.expneurol.2021.113810.
    PubMed     Abstract available


    June 2021
  21. LAPPIN JM, Darke S
    Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review.
    Exp Neurol. 2021 Jun 21:113793. doi: 10.1016/j.expneurol.2021.113793.
    PubMed     Abstract available


    May 2021
  22. BINDA KH, Lillethorup TP, Real CC, Baerentzen SL, et al
    Exercise protects synaptic density in a rat model of Parkinson's disease.
    Exp Neurol. 2021;342:113741.
    PubMed     Abstract available


  23. LIU Z, Yan A, Zhao J, Yang S, et al
    The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Exp Neurol. 2021;342:113740.
    PubMed     Abstract available


    April 2021
  24. LANGLEY MONICA R, Shivani G, Ay Muhammet PBN, Huajun J, et al
    Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
    Exp Neurol. 2021 Apr 8:113716. doi: 10.1016/j.expneurol.2021.113716.
    PubMed     Abstract available


    March 2021
  25. BECKSTEAD MJ, Howell RD
    Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.
    Exp Neurol. 2021 Mar 19:113707. doi: 10.1016/j.expneurol.2021.113707.
    PubMed     Abstract available


  26. BERGKVIST L, Johnson ME, Mercado G, Steiner JA, et al
    An extended release GLP-1 analogue increases alpha-synuclein accumulation in a mouse model of prodromal Parkinson's disease.
    Exp Neurol. 2021 Mar 13:113693. doi: 10.1016/j.expneurol.2021.113693.
    PubMed     Abstract available


    January 2021
  27. MCKNIGHT I, Hart C, Park IH, Shim JW, et al
    Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions.
    Exp Neurol. 2021;335:113523.
    PubMed     Abstract available


    December 2020
  28. SIMMNACHER K, Krach F, Schneider Y, Alecu JE, et al
    Unique signatures of stress-induced senescent human astrocytes.
    Exp Neurol. 2020;334:113466.
    PubMed     Abstract available


    November 2020
  29. SI XL, Fang YJ, Li LF, Gu LY, et al
    From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?
    Exp Neurol. 2020 Nov 5:113525. doi: 10.1016/j.expneurol.2020.113525.
    PubMed     Abstract available


    October 2020
  30. HAUMESSER JK, Beck MH, Pellegrini F, Kuhn J, et al
    Subthalamic beta oscillations correlate with dopaminergic degeneration in experimental parkinsonism.
    Exp Neurol. 2020;335:113513.
    PubMed     Abstract available


  31. SCHNEIDER JS, Marshall CA, Keibel L, Snyder NW, et al
    A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.
    Exp Neurol. 2020;335:113514.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: